Merrimack Reports Second Quarter 2018 Financial Results

Author's Avatar
Aug 07, 2018
Article's Main Image

- $18 million milestone payment received from Shire; Company continues to strengthen cash position from non-dilutive sources -

- Two clinical readouts anticipated in 2018: randomized Phase 2 SHERLOC study of MM-121 in metastatic non-small cell lung cancer and Phase 1 study of MM-310 in solid tumors -

- Conference call at 8:30 am ET today -

PR Newswire